Jane Addams College of Social Work, University of Illinois at Chicago, Chicago, IL, USA.
School of Social Work, University of Central Florida, Orlando, FL, USA.
Addiction. 2019 Nov;114(11):2016-2025. doi: 10.1111/add.14741. Epub 2019 Aug 5.
To determine whether, in the United States, higher opioid overdose-related mortality rates (OOMR) in Affordable Care Act (ACA) Medicaid expansion states relative to mortality rates in non-expansion states have been mediated by increased prescription opioid availability.
Separate mixed-effect regression models examined difference-in-difference effects of time and expansion status on Medicaid-reimbursed opioids measured in morphine milligram (mg) equivalents on all OOMR and on prescription OOMR. We used generalized structural equation models to test whether increases in Medicaid-reimbursed prescription opioid availability mediated OOMR post-Medicaid expansion.
This study used national, serial, cross-sectional data for Medicaid-reimbursed prescription opioids, Medicaid enrollment information and annual OOMR for any opioids and for prescription opioids from 49 states and the DC pre- (2008-13) and post-ACA Medicaid expansion (2014-16).
The outcome measures were OOOMR and Medicaid-reimbursed prescription opioid availability. The main input variables were time and ACA Medicaid expansion status.
Medicaid expansion states had larger increases in prescription opioid availability (b = 480, 357.8, P = 0.001) compared with non-expansion states. However, the largest increases in prescription opioid availability in expansion states were between 2009 and 2011, well before the ACA Medicaid expansion. Whereas expansion states also had higher any OOMR compared with non-expansion states (b = 3.6, P = 0.011), significant differences in prescription OOMR between expansion and non-expansion states did not emerge until 2015 (b = 1.4, P = 0.014) and 2016 (b = 4.0, P = 0.004), and Medicaid-reimbursed prescription opioid availability was not a significant mediator.
Increases in Medicaid-reimbursed prescription opioid availability in Affordable Care Act Medicaid expansion states in the United States do not appear to have mediated post-Affordable Care Act Medicaid expansion mortality rate differences, but there is still a possibility of lagged effects.
在美国,平价医疗法案(ACA)医疗补助扩张州的阿片类药物过量相关死亡率(OOMR)相对于非扩张州的死亡率是否更高,这是否与处方类阿片类药物供应增加有关。
分别使用混合效应回归模型,以研究时间和扩张状态对所有 OOMR 和处方 OOMR 中以吗啡毫克(mg)等效计量的医疗补助报销类阿片类药物的差异效应。我们使用广义结构方程模型来检验医疗补助报销的处方类阿片类药物供应增加是否在医疗补助扩张后介导了 OOMR。
本研究使用全国范围内的、连续的、横截面数据,包括医疗补助报销的处方类阿片类药物、医疗补助参保信息和 49 个州和哥伦比亚特区的每年任何类阿片类药物和处方类阿片类药物的 OOMR,数据收集时间为医疗补助法案实施前(2008-13 年)和实施后(2014-16 年)。
结局指标是 OOOMR 和医疗补助报销的处方类阿片类药物供应。主要输入变量是时间和 ACA 医疗补助扩张状态。
与非扩张州相比,医疗补助扩张州的处方类阿片类药物供应增加幅度更大(b=480,357.8,P=0.001)。然而,扩张州处方类阿片类药物供应的最大增幅发生在 2009 年至 2011 年之间,远早于 ACA 医疗补助扩张。尽管扩张州的任何 OOMR 也高于非扩张州(b=3.6,P=0.011),但直到 2015 年(b=1.4,P=0.014)和 2016 年(b=4.0,P=0.004),扩张州和非扩张州之间的处方 OOMR 差异才变得显著,而医疗补助报销的处方类阿片类药物供应并不是一个显著的中介因素。
在美国,平价医疗法案医疗补助扩张州的医疗补助报销处方类阿片类药物供应增加似乎并没有导致平价医疗法案医疗补助扩张后死亡率差异,但仍有可能存在滞后效应。